The Online Investor

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Thu., Mar. 4, 1:31 PM

Slide #73. Beam Therapeutics Inc. Guide Therapeutics, Inc.

Acquirer: Beam Therapeutics Inc. (NASDAQ:BEAM)
Acquiree: Guide Therapeutics, Inc.
Details: Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced it has completed the acquisition of Guide Therapeutics, Inc. ("GuideTx"), a developer of nonviral drug delivery vehicles for genetic medicines, further expanding the potential reach of Beam's genetic medicines into new target tissues and diseases.

Beam Therapeutics is a biotechnology company. Co. is engaged in creating a class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. Co.'s base editors have two principal components that are fused together to form a single protein: a CRISPR protein, bound to a guide RNA, that utilizes the DNA-targeting ability of CRISPR, but modified to not cause a double-stranded break; and a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA base.

BEAM SEC Filing Email Alerts Service


Open the BEAM Page at The Online Investor »

Company Name: 
Beam Therapeutics Inc
Website: 
www.beamtx.com
Sector: 
Biotechnology
Number of ETFs Holding BEAM: 
24
Total Market Value Held by ETFs: 
$467.71M
Total Market Capitalization: 
$5.35B
% of Market Cap. Held by ETFs: 
8.74%
 

Open the BEAM Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Buy (3.14 out of 4)
38th percentile
(ranked lower than approx. 62% of all stocks covered)

Analysts' Target Price:
BEAM Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.